Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 6/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 7/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 5/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.32 |
| ▸ | XPO1 | O14980 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL702655 | 0.77 | PRSS1 (0.33) | — | |
| SCHEMBL28550618 | 0.76 | CYP24A1 (0.31) | — | |
| SCHEMBL3456560 | 0.75 | — | — | |
| SCHEMBL706845 | 0.74 | KCNH2 (0.33) | TRPA1ALDH1A1CYP3A4 | |
| SCHEMBL15644380 | 0.73 | CYP1A2 (0.31) | CYP3A4 | |
| Bromide SCHEMBL7471970 | 0.72 | HIF1A (0.46) | HIF1AALDH1A1 | |
| SCHEMBL28549733 | 0.72 | MEN1 (0.30) | — | |
| SCHEMBL2008257 | 0.72 | MEN1 (0.30) | — | |
| SCHEMBL15643948 | 0.71 | PTGS2 (0.30) | — | |
| SCHEMBL2481870 | 0.71 | CYSLTR2 (0.32) | ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6800630-B2 | CYTOSTATIC ACTIVITY, INHIBITORY ACTIVITY AGAINST A SIGNAL DERIVED FROM RAS ONCOGENE PRODUCTS | SHIONOGI & CO., LTD. (JP) | 2004-10-05 | — | — | US | disclosed |
| EP-1251129-B1 | PYRIMIDINE DERIVATIVES HAVING ANTITUMOR EFFECT | SHIONOGI & CO (JP) | 2004-06-09 | — | — | EP | disclosed |
| US-20030203894-A1 | Pyrimidine derivatives having antitumor effect | SHIONOGI & CO., LTD. (JP) | 2003-10-30 | — | — | US | disclosed |
| EP-1251129-A1 | PYRIMIDINE DERIVATIVES HAVING ANTITUMOR EFFECT | SHIONOGI & CO., LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203894-A1 | Pyrimidine derivatives having antitumor effect | TYMS, TYMP, RRM1 | MIF 4322/4885TRPA1 4506/4885CYP2E1 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.